Novel Therapeutics for Neonatal Seizures

Julie M. Ziobro; Krista Eschbach; Renée A. Shellhaas

doi:10.1007/s13311-021-01085-8

Novel Therapeutics for Neonatal Seizures

Julie M. Ziobro, Krista Eschbach, Renée A. Shellhaas

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

Neonatal seizures are a common neurologic emergency for which therapies have not significantly changed in decades. Improvements in diagnosis and pathophysiologic understanding of the distinct features of acute symptomatic seizures and neonatal-onset epilepsies present exceptional opportunities for development of precision therapies with potential to improve outcomes. Herein, we discuss the pathophysiology of neonatal seizures and review the evidence for currently available treatment. We present emerging therapies in clinical and preclinical development for the treatment of acute symptomatic neonatal seizures. Lastly, we discuss the role of precision therapies for genetic neonatal-onset epilepsies and address barriers and goals for developing new therapies for clinical care.

Original language	English
Pages (from-to)	1564-1581
Number of pages	18
Journal	Neurotherapeutics
Volume	18
Issue number	3
DOIs	https://doi.org/10.1007/s13311-021-01085-8
State	Published - Jul 2021

Keywords

Antiseizure medication
Bumetanide
Hypoxic-ischemic encephalopathy
KCNQ2
Levetiracetam
Phenobarbital

Access to Document

10.1007/s13311-021-01085-8

Cite this

@article{87805caeb93a496b9b85c575187d9a67,

title = "Novel Therapeutics for Neonatal Seizures",

abstract = "Neonatal seizures are a common neurologic emergency for which therapies have not significantly changed in decades. Improvements in diagnosis and pathophysiologic understanding of the distinct features of acute symptomatic seizures and neonatal-onset epilepsies present exceptional opportunities for development of precision therapies with potential to improve outcomes. Herein, we discuss the pathophysiology of neonatal seizures and review the evidence for currently available treatment. We present emerging therapies in clinical and preclinical development for the treatment of acute symptomatic neonatal seizures. Lastly, we discuss the role of precision therapies for genetic neonatal-onset epilepsies and address barriers and goals for developing new therapies for clinical care.",

keywords = "Antiseizure medication, Bumetanide, Hypoxic-ischemic encephalopathy, KCNQ2, Levetiracetam, Phenobarbital",

author = "Ziobro, {Julie M.} and Krista Eschbach and Shellhaas, {Ren{\'e}e A.}",

note = "Funding Information: Disclosure forms provided by the authors are available with the online version of this article. Publisher Copyright: {\textcopyright} 2021, The American Society for Experimental NeuroTherapeutics, Inc.",

year = "2021",

month = jul,

doi = "10.1007/s13311-021-01085-8",

language = "English",

volume = "18",

pages = "1564--1581",

journal = "Neurotherapeutics",

issn = "1933-7213",

number = "3",

}

TY - JOUR

T1 - Novel Therapeutics for Neonatal Seizures

AU - Ziobro, Julie M.

AU - Eschbach, Krista

AU - Shellhaas, Renée A.

N1 - Funding Information: Disclosure forms provided by the authors are available with the online version of this article. Publisher Copyright: © 2021, The American Society for Experimental NeuroTherapeutics, Inc.

PY - 2021/7

Y1 - 2021/7

N2 - Neonatal seizures are a common neurologic emergency for which therapies have not significantly changed in decades. Improvements in diagnosis and pathophysiologic understanding of the distinct features of acute symptomatic seizures and neonatal-onset epilepsies present exceptional opportunities for development of precision therapies with potential to improve outcomes. Herein, we discuss the pathophysiology of neonatal seizures and review the evidence for currently available treatment. We present emerging therapies in clinical and preclinical development for the treatment of acute symptomatic neonatal seizures. Lastly, we discuss the role of precision therapies for genetic neonatal-onset epilepsies and address barriers and goals for developing new therapies for clinical care.

AB - Neonatal seizures are a common neurologic emergency for which therapies have not significantly changed in decades. Improvements in diagnosis and pathophysiologic understanding of the distinct features of acute symptomatic seizures and neonatal-onset epilepsies present exceptional opportunities for development of precision therapies with potential to improve outcomes. Herein, we discuss the pathophysiology of neonatal seizures and review the evidence for currently available treatment. We present emerging therapies in clinical and preclinical development for the treatment of acute symptomatic neonatal seizures. Lastly, we discuss the role of precision therapies for genetic neonatal-onset epilepsies and address barriers and goals for developing new therapies for clinical care.

KW - Antiseizure medication

KW - Bumetanide

KW - Hypoxic-ischemic encephalopathy

KW - KCNQ2

KW - Levetiracetam

KW - Phenobarbital

UR - http://www.scopus.com/inward/record.url?scp=85112375085&partnerID=8YFLogxK

U2 - 10.1007/s13311-021-01085-8

DO - 10.1007/s13311-021-01085-8

M3 - Review article

C2 - 34386906

AN - SCOPUS:85112375085

SN - 1933-7213

VL - 18

SP - 1564

EP - 1581

JO - Neurotherapeutics

JF - Neurotherapeutics

IS - 3

ER -

Novel Therapeutics for Neonatal Seizures

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this